organon & co. - OGN
OGN
Close Chg Chg %
6.06 -0.14 -2.31%
Open Market
5.92
-0.14 (2.31%)
Volume: 1.20M
Last Updated:
Mar 27, 2026, 2:17 PM EDT
Company Overview: organon & co. - OGN
OGN Key Data
| Open $6.06 | Day Range 5.90 - 6.15 |
| 52 Week Range 5.77 - 14.94 | Market Cap $1.57B |
| Shares Outstanding 260.32M | Public Float 259.11M |
| Beta 0.57 | Rev. Per Employee N/A |
| P/E Ratio 8.44 | EPS $0.72 |
| Yield 132.23% | Dividend $0.02 |
| EX-DIVIDEND DATE Feb 23, 2026 | SHORT INTEREST N/A |
| AVERAGE VOLUME 3.48M |
OGN Performance
| 1 Week | 0.33% | ||
| 1 Month | -17.01% | ||
| 3 Months | -15.74% | ||
| 1 Year | -58.30% | ||
| 5 Years | N/A |
OGN Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
About organon & co. - OGN
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
OGN At a Glance
Organon & Co.
30 Hudson Street
Jersey City, New Jersey 07302
| Phone | 1-551-430-6900 | Revenue | 6.22B | |
| Industry | Pharmaceuticals: Major | Net Income | 187.00M | |
| Sector | Health Technology | Employees | 10,000 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
OGN Valuation
| P/E Current | 8.506 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 9.999 |
| Price to Sales Ratio | 0.301 |
| Price to Book Ratio | 2.482 |
| Price to Cash Flow Ratio | 2.67 |
| Enterprise Value to EBITDA | 6.171 |
| Enterprise Value to Sales | 1.624 |
| Total Debt to Enterprise Value | 0.872 |
OGN Efficiency
| Revenue/Employee | 621,600.00 |
| Income Per Employee | 18,700.00 |
| Receivables Turnover | 4.338 |
| Total Asset Turnover | 0.479 |
OGN Liquidity
| Current Ratio | 1.821 |
| Quick Ratio | 1.233 |
| Cash Ratio | 0.24 |
OGN Profitability
| Gross Margin | 54.086 |
| Operating Margin | 20.512 |
| Pretax Margin | 6.837 |
| Net Margin | 3.008 |
| Return on Assets | 1.44 |
| Return on Equity | 30.556 |
| Return on Total Capital | 1.958 |
| Return on Invested Capital | 1.975 |
OGN Capital Structure
| Total Debt to Total Equity | 1,170.213 |
| Total Debt to Total Capital | 92.127 |
| Total Debt to Total Assets | 68.392 |
| Long-Term Debt to Equity | 1,162.766 |
| Long-Term Debt to Total Capital | 91.541 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Organon & Co. - OGN
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 6.17B | 6.26B | 6.40B | 6.22B | |
Sales Growth
| -2.92% | +1.44% | +2.24% | -2.92% | |
Cost of Goods Sold (COGS) incl D&A
| 2.28B | 2.52B | 2.69B | 2.85B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 212.00M | 236.00M | 277.00M | 361.00M | |
Depreciation
| 96.00M | 120.00M | 132.00M | 156.00M | |
Amortization of Intangibles
| 116.00M | 116.00M | 145.00M | 205.00M | |
COGS Growth
| -4.28% | +10.31% | +6.88% | +6.18% | |
Gross Income
| 3.89B | 3.75B | 3.71B | 3.36B | |
Gross Income Growth
| -2.11% | -3.75% | -0.88% | -9.50% | |
Gross Profit Margin
| +63.07% | +59.84% | +58.02% | +54.09% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 2.17B | 2.42B | 2.22B | 2.09B | |
Research & Development
| 471.00M | 528.00M | 469.00M | 366.00M | |
Other SG&A
| 1.70B | 1.89B | 1.75B | 1.72B | |
SGA Growth
| +3.28% | +11.31% | -8.43% | -5.86% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 149.00M | 70.00M | 93.00M | 305.00M | |
EBIT after Unusual Expense
| 1.57B | 1.26B | 1.41B | 970.00M | |
Non Operating Income/Expense
| (26.00M) | (57.00M) | (69.00M) | (31.00M) | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 422.00M | 527.00M | 529.00M | 514.00M | |
Interest Expense Growth
| +63.57% | +24.88% | +0.38% | -2.84% | |
Gross Interest Expense
| 422.00M | 527.00M | 529.00M | 514.00M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 1.12B | 673.00M | 807.00M | 425.00M | |
Pretax Income Growth
| -26.62% | -40.02% | +19.91% | -47.34% | |
Pretax Margin
| +18.17% | +10.75% | +12.60% | +6.84% | |
Income Tax
| 205.00M | (350.00M) | (57.00M) | 238.00M | |
Income Tax - Current - Domestic
| 51.00M | 48.00M | 32.00M | 32.00M | |
Income Tax - Current - Foreign
| 172.00M | 87.00M | 71.00M | 143.00M | |
Income Tax - Deferred - Domestic
| (40.00M) | (57.00M) | (58.00M) | 18.00M | |
Income Tax - Deferred - Foreign
| 22.00M | (428.00M) | (102.00M) | 45.00M | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 917.00M | 1.02B | 864.00M | 187.00M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 917.00M | 1.02B | 864.00M | 187.00M | |
Net Income Growth
| -32.12% | +11.56% | -15.54% | -78.36% | |
Net Margin Growth
| +14.85% | +16.33% | +13.49% | +3.01% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 917.00M | 1.02B | 864.00M | 187.00M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 917.00M | 1.02B | 864.00M | 187.00M | |
EPS (Basic)
| 3.6091 | 4.008 | 3.3613 | 0.7206 | |
EPS (Basic) Growth
| -32.27% | +11.05% | -16.14% | -78.56% | |
Basic Shares Outstanding
| 254.08M | 255.24M | 257.05M | 259.50M | |
EPS (Diluted)
| 3.5937 | 3.9919 | 3.334 | 0.7171 | |
EPS (Diluted) Growth
| -32.55% | +11.08% | -16.48% | -78.49% | |
Diluted Shares Outstanding
| 255.17M | 256.27M | 259.15M | 260.76M | |
EBITDA
| 1.93B | 1.56B | 1.77B | 1.64B | |
EBITDA Growth
| -6.58% | -19.06% | +13.56% | -7.83% | |
EBITDA Margin
| +31.28% | +24.96% | +27.72% | +26.32% |
Snapshot
| Average Recommendation | UNDERWEIGHT | Average Target Price | 10.00 | |
| Number of Ratings | 8 | Current Quarters Estimate | 0.829 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 3.467 | |
| Last Quarter’s Earnings | 0.63 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 3.66 | Next Fiscal Year Estimate | 3.719 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 6 | 6 | 6 | 6 |
| Mean Estimate | 0.83 | 0.93 | 3.47 | 3.72 |
| High Estimates | 0.95 | 1.07 | 3.72 | 3.94 |
| Low Estimate | 0.68 | 0.83 | 3.32 | 3.53 |
| Coefficient of Variance | 12.97 | 9.39 | 4.52 | 4.31 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 1 | 1 | 1 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 3 | 3 | 4 |
| UNDERWEIGHT | 2 | 2 | 1 |
| SELL | 2 | 2 | 3 |
| MEAN | Underweight | Underweight | Underweight |
SEC Filings for Organon & Co. - OGN
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Organon & Co. - OGN
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 5, 2026 | Matthew M. Walsh Chief Financial Officer | 172,196 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.17 per share | 1,234,645.32 |
| Mar 5, 2026 | Vittorio Nisita Head of Global Business Svcs | 60,109 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2026 | Joseph T. Morrissey Interim CEO | 98,571 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.23 per share | 712,668.33 |
| Mar 5, 2026 | Joseph T. Morrissey Interim CEO | 98,849 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2026 | Joseph T. Morrissey Interim CEO | 91,072 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.17 per share | 652,986.24 |
| Mar 5, 2026 | Joseph T. Morrissey Interim CEO | 99,126 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2026 | Aaron Falcione Chief Human Resources Officer | 84,109 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.23 per share | 608,108.07 |
| Mar 5, 2026 | Aaron Falcione Chief Human Resources Officer | 84,791 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2026 | Aaron Falcione Chief Human Resources Officer | 78,074 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.17 per share | 559,790.58 |
| Mar 5, 2026 | Aaron Falcione Chief Human Resources Officer | 86,779 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2026 | Vittorio Nisita Head of Global Business Svcs | 53,899 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.17 per share | 386,455.83 |
| Mar 5, 2026 | Vittorio Nisita Head of Global Business Svcs | 58,495 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2026 | Vittorio Nisita Head of Global Business Svcs | 58,284 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.23 per share | 421,393.32 |
| Mar 5, 2026 | Rachel A. Stahler Chief Information Officer | 98,310 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.23 per share | 710,781.30 |
| Mar 5, 2026 | Rachel A. Stahler Chief Information Officer | 98,474 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2026 | Rachel A. Stahler Chief Information Officer | 91,934 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.17 per share | 659,166.78 |
| Mar 5, 2026 | Rachel A. Stahler Chief Information Officer | 100,409 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2026 | Matthew M. Walsh Chief Financial Officer | 180,751 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.23 per share | 1,306,829.73 |
| Mar 5, 2026 | Matthew M. Walsh Chief Financial Officer | 184,216 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2026 | Matthew M. Walsh Chief Financial Officer | 187,083 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |